Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia.

Lambert M, Schimmelmann BG, Naber D, Schacht A, Karow A, Wagner T, Czekalla J.

J Clin Psychiatry. 2006 Nov;67(11):1690-7.

PMID:
17196047
2.

Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia.

Lambert M, Naber D, Schacht A, Wagner T, Hundemer HP, Karow A, Huber CG, Suarez D, Haro JM, Novick D, Dittmann RW, Schimmelmann BG.

Acta Psychiatr Scand. 2008 Sep;118(3):220-9. doi: 10.1111/j.1600-0447.2008.01213.x.

PMID:
18699954
3.

Establishing remission and good clinical functioning in schizophrenia: predictors of best outcome with long-term risperidone long-acting injectable treatment.

Lambert M, De Marinis T, Pfeil J, Naber D, Schreiner A.

Eur Psychiatry. 2010 May;25(4):220-9. doi: 10.1016/j.eurpsy.2009.09.001. Epub 2009 Nov 18.

PMID:
19926263
4.

Remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia.

Karow A, Moritz S, Lambert M, Schöttle D, Naber D; EGOFORS Initiative.

Eur Psychiatry. 2012 Aug;27(6):401-5. doi: 10.1016/j.eurpsy.2011.01.012. Epub 2011 May 12.

PMID:
21570262
5.

Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study.

Novick D, Haro JM, Suarez D, Lambert M, Lépine JP, Naber D.

Psychopharmacology (Berl). 2007 May;191(4):1015-22. Epub 2007 Feb 20.

PMID:
17310386
6.

Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study.

Novick D, Haro JM, Suarez D, Vieta E, Naber D.

Schizophr Res. 2009 Mar;108(1-3):223-30. doi: 10.1016/j.schres.2008.11.007. Epub 2008 Dec 13.

PMID:
19070991
7.

Symptomatic resolution among Chinese patients with schizophrenia and associated factors.

Li CT, Su TP, Chou YH, Lee YC, Liu ME, Ku HL, Shan IK, Bai YM.

J Formos Med Assoc. 2010 May;109(5):378-88. doi: 10.1016/S0929-6646(10)60066-6.

8.

Remission as perceived by people with schizophrenia, family members and psychiatrists.

Karow A, Naber D, Lambert M, Moritz S; EGOFORS Initiative.

Eur Psychiatry. 2012 Aug;27(6):426-31. doi: 10.1016/j.eurpsy.2011.01.013. Epub 2011 May 14.

PMID:
21571506
9.

Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride.

Lambert M, Naber D, Eich FX, Schacht M, Linden M, Schimmelmann BG.

Acta Psychiatr Scand. 2007 Feb;115(2):106-13.

PMID:
17244174
10.

Prevalence of remission and recovery in schizophrenia in the Czech Republic.

Prikryl R, Kholova M, Kucerova HP, Ceskova E.

Compr Psychiatry. 2013 Oct;54(7):1111-6. doi: 10.1016/j.comppsych.2013.05.006. Epub 2013 Jun 27.

PMID:
23810077
11.

The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone.

Buckley PF, Harvey PD, Bowie CR, Loebel A.

Schizophr Res. 2007 Aug;94(1-3):99-106. Epub 2007 May 11.

PMID:
17499480
12.

Symptomatic remission and cognitive impairment in first-episode schizophrenia: a prospective 3-year follow-up study.

Chang WC, Ming Hui CL, Yan Wong GH, Wa Chan SK, Ming Lee EH, Hai Chen EY.

J Clin Psychiatry. 2013 Nov;74(11):e1046-53. doi: 10.4088/JCP.13m08355.

PMID:
24330905
13.

Symptomatic remission and patient quality of life in an observational study of schizophrenia: is there a relationship?

Haro JM, Novick D, Perrin E, Bertsch J, Knapp M.

Psychiatry Res. 2014 Dec 15;220(1-2):163-9. doi: 10.1016/j.psychres.2014.07.034. Epub 2014 Aug 15.

PMID:
25194449
14.

Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study.

Haro JM, Novick D, Suarez D, Alonso J, Lépine JP, Ratcliffe M; SOHO Study Group.

J Clin Psychopharmacol. 2006 Dec;26(6):571-8.

PMID:
17110813
15.

The beneficial effects of combining pharmacological and psychosocial treatment on remission and functional outcome in outpatients with schizophrenia.

Valencia M, Fresan A, Juárez F, Escamilla R, Saracco R.

J Psychiatr Res. 2013 Dec;47(12):1886-92. doi: 10.1016/j.jpsychires.2013.09.006. Epub 2013 Sep 19.

PMID:
24112947
16.

Remission in the outpatient care of schizophrenia: 3-year results from the Schizophrenia Outpatients Health Outcomes (SOHO) study in France.

Gasquet I, Haro JM, Tcherny-Lessenot S, Chartier F, Lépine JP.

Eur Psychiatry. 2008 Oct;23(7):491-6. doi: 10.1016/j.eurpsy.2008.03.012. Epub 2008 Jun 24.

PMID:
18573640
17.

A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial.

Stahl SM, Malla A, Newcomer JW, Potkin SG, Weiden PJ, Harvey PD, Loebel A, Watsky E, Siu CO, Romano S.

J Clin Psychopharmacol. 2010 Aug;30(4):425-30. doi: 10.1097/JCP.0b013e3181e69042. Erratum in: J Clin Psychopharmacol. 2010 Oct;30(5):652.

PMID:
20571437
18.

Remission in first-episode psychosis: predictor variables and symptom improvement patterns.

Emsley R, Oosthuizen PP, Kidd M, Koen L, Niehaus DJ, Turner HJ.

J Clin Psychiatry. 2006 Nov;67(11):1707-12.

PMID:
17196049
19.

Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study.

Haynes VS, Zhu B, Stauffer VL, Kinon BJ, Stensland MD, Xu L, Ascher-Svanum H.

BMC Psychiatry. 2012 Dec 5;12:222. doi: 10.1186/1471-244X-12-222.

20.

Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?

Schennach-Wolff R, Jäger M, Obermeier M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Kühn KU, Lemke MR, Rüther E, Klingberg S, Gastpar M, Seemüller F, Möller HJ, Riedel M.

World J Biol Psychiatry. 2010 Aug;11(5):729-38. doi: 10.3109/15622971003690289.

PMID:
20380620

Supplemental Content

Support Center